Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
74.24(c) 73.8(c) 73.57(c) 74.63(c) 74.85 Last
4 203 828 4 873 177 3 104 509 3 481 465 3 575 183 Volume
+1.09% -0.59% -0.31% +1.44% +0.29% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 52 202 M - -
Net income 2021 15 713 M - -
Net Debt 2021 20 298 M - -
P/E ratio 2021 12,5x
Yield 2021 4,37%
Sales 2022 54 135 M - -
Net income 2022 10 578 M - -
Net Debt 2022 16 089 M - -
P/E ratio 2022 15,6x
Yield 2022 4,48%
Capitalization 167 B 181 B -
EV / Sales 2021 3,60x
EV / Sales 2022 3,39x
Nbr of Employees 108 000
Free-Float 85,7%
More Financials
Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and... 
Sector
Pharmaceuticals
Calendar
12/09Presentation
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVARTIS AG
08:37aHSBC Lowers Price Target on Novartis, Maintains Hold Recommendation
MT
01:57aNOVARTIS AG : Gets a Buy rating from Jefferies
MD
12/06Fitch Holds Roche's Rating on Strong Financial Profile; Outlook Stable
MT
12/06Roche Wraps Up Share Repurchase Deal With Novartis, Affirms FY21 Outlook
MT
12/06NOVARTIS : Bilateral transaction between Novartis and Roche successfully closed
PU
12/06AlphaValue/Baader Europe Lowers Price Target on Novartis, Maintains Buy Recommendation
MT
12/06Exane BNP Paribas Downgrades Novartis to Neutral from Outperform
MT
12/06Novartis working on pan-coronavirus oral treatment, CEO says
RE
12/06NOVARTIS AG : Deutsche Bank reaffirms its Sell rating
MD
12/03Bryan Garnier Downgrades Novartis to Neutral from Buy
MT
12/03NOVARTIS AG : UBS reaffirms its Neutral rating
MD
12/03NOVARTIS AG : Sell rating from JP Morgan
MD
12/03Drugmakers cut prices by 62% on average to get China state insurance listing
RE
12/02Novartis Mulls Bolt-On Acquisitions
CI
12/02GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
More news
News in other languages on NOVARTIS AG
12:16pBOURSE ZURICH : les indices poursuivent sur la lancée positive de la veille
12:15pAKTIEN SCHWEIZ SCHLUSS : SMI schliesst über 12'500 Punkten fester
11:43aAktien Schweiz knüpfen an Vortagesgewinne an
11:08aRésumé des principales informations économiques du mardi 7 décembre
10:51aDPA-AFX ÜBERBLICK : MERGERS & ACQUISITIONS vom 07.12.2021
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 74,85 $
Average target price 96,60 $
Spread / Average Target 29,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-10.78%180 397
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321